Quoted from Reportable News: San Francisco/January 12, 2020 – Lowell Therapeutics, Inc., (Lowell) today announced that it has scheduled a company presentation at the Biotech Showcase™ 2020, to be held January 13-15, during the most important week in healthcare at the Hilton San Francisco Union Square. James Wilkie, President & CEO will be presenting Lowell […]
News
As posted by MedTechDive: “Manufacturers of breakthrough devices may have an easier path to CMS reimbursement under an alternative new technology add-on payment model outlined in the Inpatient Prospective Payment System rule for 2020, finalized Friday.” Read the full article here
James Wilkie – President & CEO of Lowell Therapeutics will be speaking at the Bio CEO & Investor Conference on Tuesday, February 11, 2020 at 1:30 PM (EST). Lowell Therapeutics – Bio CEO & Investor Conference About the Conference
Lowell Therapeutics President & CEO James Wilkie sat down with Proactive’s Christine Corrado at BIO CEO in New York.
Lowell Therapeutics (LTX) today announced that the FDA has granted Breakthrough Device Designation for Niyad. Niyad provides anticoagulation for patients in the ICU on an artificial kidney machine. When commercialized, Niyad will be the only FDA-approved regional anticoagulant and provides an option for anticoagulation that does not exist today and is an improvement over the […]
BOSTON, Sept. 14, 2020 — Lowell Therapeutics, Inc. (LTX), a biopharmaceutical company, announced today that the company has been selected by the M2D2 Center of the University of Massachusetts as a finalist in its annual competition of rising stars in the biotech community. James Wilkie, President & CEO, will provide a corporate overview on Thursday, […]